At the conclusion of this session, participants will be able to:
1-does the degree of Lp(a) elevation parallel the patient's risk (eg do I treat a patient with Lp(a) >1000mg/L similar to a patient with Lp(a) 375mg/L, assuming all other RFs are equal)? 2-Is there ever any benefit/indication to switching statins for either optimization of treatment, or, minimizing side effects? 3-In terms of lifestyle modifications, what are the main 'soundbites' you share with the patient that are easy to convey and doable? 4-what's your smoking cessation treatment modality of choice with these patients? 5-Given that Framingham is only assessing for short term risk, is there value in Reynold's score, or other calculator to look at lifetime/longer term risk? 6-Why do some labs take up to 2 mths to report Lp(a) values while others send the results shortly after test is done?
Do we need to continue verifying cholesterol each year for patients under statine?
1. How often should we screen for dyslipidemia after initial screening in those at risk for ASCVD, after the initial screen calculates no need for a statin? My understanding is that once yearly is far too much in primary prevention. Can you give the optimal screening frequency in primary prevention if the initial screening does not reveal a need for a statin? 2. If a statin is indicated as in the guidelines for primary prevention or for a statin-indicated condition, how soon after starting the stain should the non HDL/LDL/Apo B be repeated to ensure that targets have been met ? 3. So many elderly patients fit the definition for Chronic kidney disease (a statin-indicated condition). If a 75 year old patient (or older) has CKD by definition and is not on a statin, should a statin be started? At what age does the benefit of starting a statin for CKD start to decline? Up until what age would you start a statin for CKD? 4. I see many patients with incidental findings of atheromatous plaque on the aorta and arterial calcification (outside the coronary arteries) on imaging. (I realize coronary artery calcification is a separate issue). Should all these patients be started on a statin, or just the patients with atheromatous plaque on aorta? Does it depend on the age of the patient? If the decision to start a statin is made for atheromatous plaque on the aorta, should a low dose ASA be started as well?